Phase 2 Trial Shows Antitumor Activity in Metastatic Clear Cell RCC
Chung-Han Lee, MD, PhD, discusses the efficacy of a phase 2 study of pembrolizumab and lenvatinib in patient with metastatic clear cell renal cell carcinoma who have progressed on an immune checkpoint inhibitor.
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the efficacy of a phase 2 study (NCT02501096) of pembrolizumab (Keytruda) and lenvatinib (Lenvima) in patient with metastatic clear cell renal cell carcinoma (ccRCC) who have progressed on an immune checkpoint inhibitor.
Lee says that in this setting, the trial was able to demonstrate a high objective response rate of 55% in patients by immune-related Response Evaluation Criteria in Solid Tumors (RECIST) and 52% by RECIST version 1.1. For the patients who responded, the median duration of response was about 10 months, and most patients with metastatic ccRCC remained on treatment at the time of the data cutoff, which was April 9, 2020. Forty-six of the 91 patients with confirmed partial responses.
For the entire group of patients on this trial, there was a median progression-free survival of 11.7 months, and 45% of the total population remained progression-free at the 12-month time point, according to Lee. No new safety signals were observed in this trial, and the most common treatment-related adverse events were fatigue, diarrhea, and proteinuria.
<< View more resources and information regarding renal cell carcinoma
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More
